Associated Papers
Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage.
Li L et al.
Cancer Cell, 2026
Systematic Characterization of Cancer-Associated SPOP Mutants Reveals Novel and Reprogrammable Degradative Activities.
Caldwell AG et al.
Chembiochem : a European Journal of Chemical Biology, 2026
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Wang R et al.
Cancer Research Communications, 2025
Systematic characterization of cancer-associated SPOP mutants reveals novel and reprogrammable degradative activities.
Caldwell AG et al.
Biorxiv : the Preprint Server for Biology, 2025
Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population.
Yang B et al.
World Journal of Surgical Oncology, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression.
Fiorentino V et al.
Pathologica, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment.
Wang Z et al.
The Journal of Clinical Investigation, 2025
Sequence rules for a long SPOP-binding degron required for protein ubiquitylation.
Makhlouf L et al.
The Biochemical Journal, 2025
SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer.
Zhang H et al.
Jci Insight, 2025
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H et al.
Nature Reviews. Cancer, 2025
Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment.
Lee J et al.
Plos Genetics, 2025
Updates on SPOP Gene Mutations in Prostate Cancer and Computational Insights From TCGA cBioPortal Database.
Zakari S et al.
Scientifica, 2025
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
Rocca C et al.
Anticancer Research, 2023
Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A et al.
The Prostate, 2023
Mass spectrometry-based targeted proteomics for analysis of protein mutations.
Lin TT et al.
Mass Spectrometry Reviews, 2023
CHD1, a multifaceted epigenetic remodeler in prostate cancer.
Li H et al.
Frontiers in Oncology, 2023
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y et al.
Cell Death and Differentiation, 2022
The evolving landscape of prostate cancer somatic mutations.
Cotter K et al.
The Prostate, 2022
Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A et al.
Cell Biology International, 2022
SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q et al.
Cell Death and Differentiation, 2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Mo X et al.
Cell, 2022
UbE3-APA: a bioinformatic strategy to elucidate ubiquitin E3 ligase activities in quantitative proteomics study.
Gong Y et al.
Bioinformatics (oxford, England), 2022
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J et al.
Jci Insight, 2022
Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M et al.
The Prostate, 2022
Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer.
Zhou J et al.
Frontiers in Oncology, 2022
SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S et al.
The Prostate, 2021
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z et al.
Neoplasia (new York, N.y.), 2021
Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.
Armstrong AJ et al.
Prostate Cancer and Prostatic Diseases, 2021
Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X et al.
Nucleic Acids Research, 2021
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L et al.
Cancer Research, 2021
2-kupl: mapping-free variant detection from DNA-seq data of matched samples.
Wang Y et al.
Bmc Bioinformatics, 2021
ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication.
Wang D et al.
Science Advances, 2021
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN et al.
Jci Insight, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF et al.
Jama Oncology, 2021
Comprehensive characterization of protein-protein interactions perturbed by disease mutations.
Cheng F et al.
Nature Genetics, 2021
A disease-relevant mutation of SPOP highlights functional significance of ATM-mediated DNA damage response.
Xiao M et al.
Signal Transduction and Targeted Therapy, 2021
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.
Ma J et al.
Frontiers in Oncology, 2021
Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway.
Peterson J et al.
Scientific Reports, 2020